뇌종양 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Brain Cancer Diagnostics Market - Scope of Report

TMR's report on the global brain cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global brain cancer diagnostics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global brain cancer diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the brain cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global brain cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global brain cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global brain cancer diagnostics market.

The report delves into the competitive landscape of the global brain cancer diagnostics market. Key players operating in the global brain cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global brain cancer diagnostics market profiled in this report.

Key Questions Answered in Global brain cancer diagnostics Market Report:

• What is the sales/revenue generated by brain cancer diagnostics across all regions during the forecast period?
• What are the opportunities in the global brain cancer diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Brain Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global brain cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global brain cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global brain cancer diagnostics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Brain Cancer Diagnostics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Brain Cancer Diagnostics Market Analysis and Forecasts, 2023-2031

5. Key Insights

• 5.1. Brain Tumor Epidemiology
• 5.2. Current Trends in Diagnostic and Therapeutic Imaging of Brain Tumors
• 5.3. Technological advancements in cancer diagnostics
• 5.4. COVID-19 Impact Analysis

6. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Diagnostic Technique

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Diagnostic Technique, 2023-2031
  • 6.3.1. Imaging Techniques
    • 6.3.1.1. Magnetic Resonance Imaging (MRI)
    • 6.3.1.2. Computed Tomography (CT) Scan
    • 6.3.1.3. PET Scan or PET-CT Scan
    • 6.3.1.4. (SPECT) Scan
  • 6.3.2. Tissue Sampling/Biopsy
  • 6.3.3. Molecular Diagnostics
  • 6.3.4. Others
• 6.4. Market Attractiveness Analysis, by Diagnostic Technique

7. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Brain Cancer Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Brain Cancer Type, 2023-2031
  • 7.3.1. Gliomas
  • 7.3.2. Meningiomas
  • 7.3.3. Pituitary Tumors
  • 7.3.4. Others
• 7.4. Market Attractiveness Analysis, by Brain Cancer Type

8. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by End-user, 2023-2031
  • 8.3.1. Hospitals
  • 8.3.2. Diagnostic Laboratories
  • 8.3.3. Cancer Hospitals/Centers
• 8.4. Market Attractiveness Analysis, by End-user

9. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Brain Cancer Diagnostics Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Diagnostic Technique, 2023-2031
  • 10.2.1. Imaging Techniques
    • 10.2.1.1. Magnetic Resonance Imaging (MRI)
    • 10.2.1.2. Computed Tomography (CT) Scan
    • 10.2.1.3. PET Scan or PET-CT Scan
    • 10.2.1.4. (SPECT) Scan
  • 10.2.2. Tissue Sampling/Biopsy
  • 10.2.3. Molecular Diagnostics
  • 10.2.4. Others
• 10.3. Market Value Forecast, by Brain Cancer Type, 2023-2031
  • 10.3.1. Gliomas
  • 10.3.2. Meningiomas
  • 10.3.3. Pituitary Tumors
  • 10.3.4. Others
• 10.4. Market Value Forecast, by End-user, 2023-2031
  • 10.4.1. Hospitals
  • 10.4.2. Diagnostic Laboratories
  • 10.4.3. Cancer Hospitals/Centers
• 10.5. Market Value Forecast, by Country, 2023-2031
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Diagnostic Technique
  • 10.6.2. By Brain Cancer Type
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Brain Cancer Diagnostics Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Diagnostic Technique, 2023-2031
  • 11.2.1. Imaging Techniques
    • 11.2.1.1. Magnetic Resonance Imaging (MRI)
    • 11.2.1.2. Computed Tomography (CT) Scan
    • 11.2.1.3. PET Scan or PET-CT Scan
    • 11.2.1.4. (SPECT) Scan
  • 11.2.2. Tissue Sampling/Biopsy
  • 11.2.3. Molecular Diagnostics
  • 11.2.4. Others
• 11.3. Market Value Forecast, by Brain Cancer Type, 2023-2031
  • 11.3.1. Gliomas
  • 11.3.2. Meningiomas
  • 11.3.3. Pituitary Tumors
  • 11.3.4. Others
• 11.4. Market Value Forecast, by End-user, 2023-2031
  • 11.4.1. Hospitals
  • 11.4.2. Diagnostic Laboratories
  • 11.4.3. Cancer Hospitals/Centers
• 11.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Diagnostic Technique
  • 11.6.2. By Brain Cancer Type
  • 11.6.3. By End-user
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Brain Cancer Diagnostics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Diagnostic Technique, 2023-2031
  • 12.2.1. Imaging Techniques
    • 12.2.1.1. Magnetic Resonance Imaging (MRI)
    • 12.2.1.2. Computed Tomography (CT) Scan
    • 12.2.1.3. PET Scan or PET-CT Scan
    • 12.2.1.4. (SPECT) Scan
  • 12.2.2. Tissue Sampling/Biopsy
  • 12.2.3. Molecular Diagnostics
  • 12.2.4. Others
• 12.3. Market Value Forecast, by Brain Cancer Type, 2023-2031
  • 12.3.1. Gliomas
  • 12.3.2. Meningiomas
  • 12.3.3. Pituitary Tumors
  • 12.3.4. Others
• 12.4. Market Value Forecast, by End-user, 2023-2031
  • 12.4.1. Hospitals
  • 12.4.2. Diagnostic Laboratories
  • 12.4.3. Cancer Hospitals/Centers
• 12.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Diagnostic Technique
  • 12.6.2. By Brain Cancer Type
  • 12.6.3. By End-user
  • 12.6.4. By Country/Sub-region

13. Latin America Brain Cancer Diagnostics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Diagnostic Technique, 2023-2031
  • 13.2.1. Imaging Techniques
    • 13.2.1.1. Magnetic Resonance Imaging (MRI)
    • 13.2.1.2. Computed Tomography (CT) Scan
    • 13.2.1.3. PET Scan or PET-CT Scan
    • 13.2.1.4. (SPECT) Scan
  • 13.2.2. Tissue Sampling/Biopsy
  • 13.2.3. Molecular Diagnostics
  • 13.2.4. Others
• 13.3. Market Value Forecast, by Brain Cancer Type, 2023-2031
  • 13.3.1. Gliomas
  • 13.3.2. Meningiomas
  • 13.3.3. Pituitary Tumors
  • 13.3.4. Others
• 13.4. Market Value Forecast, by End-user, 2023-2031
  • 13.4.1. Hospitals
  • 13.4.2. Diagnostic Laboratories
  • 13.4.3. Cancer Hospitals/Centers
• 13.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Diagnostic Technique
  • 13.6.2. By Brain Cancer Type
  • 13.6.3. By End-user
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Brain Cancer Diagnostics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Diagnostic Technique, 2023-2031
  • 14.2.1. Imaging Techniques
    • 14.2.1.1. Magnetic Resonance Imaging (MRI)
    • 14.2.1.2. Computed Tomography (CT) Scan
    • 14.2.1.3. PET Scan or PET-CT Scan
    • 14.2.1.4. (SPECT) Scan
  • 14.2.2. Tissue Sampling/Biopsy
  • 14.2.3. Molecular Diagnostics
  • 14.2.4. Others
• 14.3. Market Value Forecast, by Brain Cancer Type, 2023-2031
  • 14.3.1. Gliomas
  • 14.3.2. Meningiomas
  • 14.3.3. Pituitary Tumors
  • 14.3.4. Others
• 14.4. Market Value Forecast, by End-user, 2023-2031
  • 14.4.1. Hospitals
  • 14.4.2. Diagnostic Laboratories
  • 14.4.3. Cancer Hospitals/Centers
• 14.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Diagnostic Technique
  • 14.6.2. By Brain Cancer Type
  • 14.6.3. By End-user
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2021)
• 15.3. Company Profiles
  • 15.3.1. GE Healthcare
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Strategic Overview
    • 15.3.1.5. SWOT Analysis
  • 15.3.2. Siemens Healthineers
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Strategic Overview
    • 15.3.2.5. SWOT Analysis
  • 15.3.3. Philips Healthcare
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Strategic Overview
    • 15.3.3.5. SWOT Analysis
  • 15.3.4. Thermo Fisher Scientific
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Strategic Overview
    • 15.3.4.5. SWOT Analysis
  • 15.3.5. Roche Diagnostics
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Strategic Overview
    • 15.3.5.5. SWOT Analysis
  • 15.3.6. Abbott Laboratories
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Strategic Overview
    • 15.3.6.5. SWOT Analysis
  • 15.3.7. Illumina, Inc.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Strategic Overview
    • 15.3.7.5. SWOT Analysis
  • 15.3.8. Hologic, Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Strategic Overview
    • 15.3.8.5. SWOT Analysis
  • 15.3.9. Agilent Technologies
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Strategic Overview
    • 15.3.9.5. SWOT Analysis
  • 15.3.10. Bio-Rad Laboratories
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Strategic Overview
    • 15.3.10.5. SWOT Analysis